Peritoneal Carcinomatosis Market

• Peritoneal carcinomatosis is the intraperitoneal dissemination of any tumor that does not originate from the peritoneum itself. It is the most common diffuse peritoneal disease.
• The peritoneum is the second most prevalent site of metastatic spread, following the liver.
• About 7 out of every 1 million people are diagnosed with peritoneal carcinomatosis annually.
• The disease may be more prevalent in certain ethnic groups, with potentially higher incidence rates observed in white women compared to black women.
• Peritoneal carcinomatosis most commonly occurs in women, with the average age at diagnosis being around 60 years.
• Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is increasingly recognized as a standard treatment for patients with peritoneal carcinomatosis. Although maximum patients experience relapse after multimodal treatment, incorporating surgery is believed to enhance overall survival and maintain quality of life.
• Currently, there are no FDA-approved drugs for treatment of peritoneal carcinomatosis. However, targeted therapies like bevacizumab (anti-VEGF) and PARP inhibitors are sometimes used, especially for ovarian cancers with BRCA mutations. These therapies show promise when combined with chemotherapy.
• The current development pipeline for peritoneal carcinomatosis features Radspherin, a novel radiopharmaceutical therapy being developed by Oncoinvent.
• In June 2025, Oncoinvent announced positive final data from Phase I/IIa trial of Radspherin in patients with colorectal peritoneal metastases. Data demonstrate sustained peritoneal disease control and reinforce the potential of Oncoinvent’s novel radiopharmaceutical therapy to target peritoneal disease in colorectal cancer (CRC).
• Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) is a novel minimally invasive chemotherapy regimen that reduces pain and may benefit patients with peritoneal carcinomatosis when added to systemic therapy.

DelveInsight's “Peritoneal Carcinomatosis Market– Market Insight, Epidemiology and Market Forecast – 2040” report delivers an in-depth analysis of peritoneal carcinomatosis, market, and clinical development in Peritoneal Carcinomatosis. In addition to this, the report provides historical and forecasted epidemiology and market data as well as a detailed analysis of the peritoneal carcinomatosis market trends in the United States, EU4 (Germany, France, Italy, and Spain ), the United Kingdom, and Japan.

Peritoneal Carcinomatosis market report provides real-world prescription pattern analysis, emerging drugs assessment, market share, and uptake/adoption pattern of individual therapies, as well as historical and forecasted peritoneal carcinomatosis market size from 2020 to 2040 in the 7MM. The report also covers current peritoneal carcinomatosis treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

Peritoneal Carcinomatosis Understanding and Treatment Algorithm

Peritoneal Carcinomatosis Overview 

Peritoneal Carcinomatosis is a rare form of cancer that develops in peritoneum (thin lining of the abdominal cavity).   It is primarily caused by the metastasis of other cancers, most commonly from the ovaries, gastrointestinal tract (including colon, stomach, and appendix), and pancreas. The risk factors of peritoneal carcinomatosis includes age, BRCA genetic mutations, hormone replacement therapy, obesity, endometriosis and family history of ovarian or peritoneal cancer. 

The symptoms of peritoneal carcinomatosis typically appear in late stages when the cancer cells grow significantly and affect surrounding organs. Diarrhea, constipation, nausea, abdominal swelling and pain, bloating, weight loss or gain, extreme fatigue, and loss of appetite are some its common symptoms. As the cancer spreads, urinary symptoms may occur if nearby organs like the bladder or ureters are affected, along with shortness of breath due to pressure from fluid accumulation.

Peritoneal Carcinomatosis Diagnosis

The diagnosis of peritoneal carcinomatosis typically involves a combination of medical history evaluation, physical examination, imaging tests, and sometimes invasive procedures due to its diffuse spread across the peritoneal lining without distinct masses. Computed tomography (CT) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET scans) are often the initial steps to visualize tumor spread and ascites. Further, peritoneal washing cytology, staging laparoscopy and biopsy are often performed to confirm diagnosis and assess tumor burden accurately. Tumor marker blood tests and newer methods like circulating tumor DNA analysis may assist but are not definitive. The peritoneal carcinomatosis index (PCI) is used to assess tumor spread and guide treatment planning. 

Further details related to country-based variations in diagnosis are provided in the report

Peritoneal Carcinomatosis Treatment

The treatment is often challenging because peritoneal carcinomatosis usually arises from advanced invasive cancers that has spread from another cancer.  The primary aim of treatment is to manage symptoms, ease pain, and improve patient’s quality of life. The mainstay of treatment is a combination of cytoreductive surgery (CRS) hyperthermic intraperitoneal chemotherapy (HIPEC) and peritonectomy. CRS aims to surgically remove all visible tumor deposits from the peritoneum and affected organs, while HIPEC involves circulating heated chemotherapy directly into the abdominal cavity to kill residual microscopic cancer cells. This approach has significantly improved survival for selected patients, especially those with colorectal, ovarian, gastric cancers, and other peritoneal surface malignancies.

Further details related to treatment will be provided in the report…

Peritoneal Carcinomatosis Epidemiology

The Peritoneal Carcinomatosis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented as total cases of different cancer types associated with peritoneal carcinomatosis, total diagnosed cases of peritoneal carcinomatosis, and total treated cases of peritoneal carcinomatosis in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2040. 

• About 7 out of every 1 million people are diagnosed with peritoneal carcinomatosis annually.
• Approximately 40–60% of patients who undergo curative gastrectomy followed by systemic chemotherapy experience peritoneal carcinomatosis as the sole site of cancer recurrence.
• Peritoneal carcinomatosis accounts approximately 10% of all cases of peritoneal and ovarian cancers combined.

Peritoneal Carcinomatosis Drug Chapters

The drug chapter segment of peritoneal carcinomatosis report encloses a detailed analysis of peritoneal carcinomatosis-marketed drugs and emerging pipeline drugs. It also deep dives into peritoneal carcinomatosis’s pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations. 

Emerging Therapies

Radspherin: Oncoinvent 

Radspherin is a novel alpha-emitting radioactive micro particle suspension designed for local treatment of metastatic cancers in body cavities. It consists of an alpha radiating micro particle suspension that is instilled in the targeted body cavity. This allows local radiopharmaceutical therapy of that body cavity, without the need to use systemic administration. Radspherin has received Fast Track Designation (FTD) from FDA for the treatment of patients with peritoneal metastases from ovarian cancer. 

Near-term significant milestones for Radspherin:

• Phase I/IIa Colorectal Cancer: Key Readout Expected Late H1 2025
• Phase I Ovarian Cancer: 24-Month Maturity Data Targeted for H2 2025
• Phase II Ovarian Cancer: Interim Readout Projected for Late H2 2026

Note: Detailed emerging therapies assessment will be provided in the final report.

Drug Class Insights

Ionizing Radiation Emitters (Radspherin) 

Radspherin is a microparticle-based intraperitoneal therapy that delivers alpha-emitting radionuclides directly into the peritoneal cavity following cytoreductive surgery. The drug consists of radium-224, an alpha emitter, encapsulated within biodegradable microspheres.

• Alpha particles have high energy but a very short penetration range (~50–100 μm), which allows them to kill tumor cells with high precision while sparing surrounding healthy tissues.
• When administered intraperitoneally, Radspherin disperses within the peritoneal cavity, where residual microscopic cancer cells remain after surgery.
• The alpha radiation induces double-strand DNA breaks in cancer cells, leading to irreversible cell death (apoptosis or necrosis), particularly in areas where standard systemic chemotherapy has limited access.

This targeted local radiotherapy approach aims to reduce recurrence of peritoneal metastases, especially in peritoneal carcinomatosis from ovarian or colorectal cancer, by eradicating microscopic residual disease post-surgery.

Peritoneal Carcinomatosis Market Outlook

Peritoneal carcinomatosis is commonly associated with advanced stages of gastrointestinal, ovarian, and other abdominal cancers, leading to significant challenges in treatment and poor prognosis. However, advancements in surgical techniques and systemic therapies have led to more comprehensive treatment approaches aimed at improving survival and quality of life.

Currently, a combination of cytoreductive surgery (CRS) and intraperitoneal chemotherapy (HIPEC or EPIC) is regarded as the best therapeutic option for patients with peritoneal carcinomatosis. CRS surgically removes visible tumors from the peritoneal cavity, often including organs like bowel and omentum, followed by HIPEC, which delivers heated chemotherapy inside the abdomen to kill remaining microscopic cancer cells.

Systemic chemotherapy with platinum-based drugs and taxanes is used before or after surgery but poorly penetrates the peritoneum, often leaving residual disease. Neoadjuvant chemotherapy (NACT), given prior to surgery, helps shrink tumors, improving the likelihood of successful cytoreduction and better surgical outcomes in responsive patients. 

Targeted therapies like bevacizumab (anti-VEGF) and PARP inhibitors are sometimes used, especially for ovarian cancers with BRCA mutations. These therapies show promise when combined with chemotherapy.

The development pipeline for peritoneal carcinomatosis currently highlights Radspherin, an emerging radiopharmaceutical therapy being advanced by Oncoinvent. 

Peritoneal Carcinomatosis Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2025–2040. The landscape of peritoneal carcinomatosis treatment has experienced a profound transformation with the uptake of novel medicines. These innovative therapies are redefining standards of care. 

Further detailed analysis of emerging therapies' drug uptake in the report.

Peritoneal Carcinomatosis Pipeline Development Activities

The report provides insights into different therapeutic candidates in the marketed and emerging stages. It also analyses key players involved in developing targeted therapeutics. 

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Peritoneal Carcinomatosis therapies. 

KOL Views

To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Medical/scientific writers, Professors, and others.

DelveInsight’s analysts connected with 15+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Centers such as University Hospital Regensburg, Sapienza University of Rome, Hospital Barmherzige Brüder Regensburg, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or Peritoneal Carcinomatosis market trends. 

Qualitative Analysis

We perform qualitative and market intelligence analysis using various approaches, such as SWOT and conjoint analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst’s discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, designation, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The analyst analyzes multiple emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry.

In efficacy, the trial’s primary and secondary outcome measures are evaluated. 

Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials.

Market Access and Reimbursement

Reimbursement may be referred to as the negotiation of a price between a manufacturer and a payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug. In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs, including Medicare, Medicaid, Health Insurance Program (CHIP), and the state and federal health insurance marketplaces, are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs) and third-party organizations that provide services and educational programs to aid patients are also present.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report

• The report covers a segment of key events, an executive summary, a descriptive overview of Peritoneal Carcinomatosis, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the Peritoneal Carcinomatosis market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT and conjoint analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Peritoneal Carcinomatosis market.

Peritoneal Carcinomatosis Report Insights

• Patient Population
• Therapeutic Approaches
• Peritoneal Carcinomatosis Pipeline Analysis
• Peritoneal Carcinomatosis Market Size and Trends
• Existing and Future Market Opportunity 

Peritoneal Carcinomatosis Report Key Strengths

• Sixteen-Year Forecast
• 7MM Coverage 
• Peritoneal Carcinomatosis Epidemiology Segmentation
• Key Cross Competition 
• Conjoint analysis
• Drugs Uptake and Key Market Forecast Assumptions

Peritoneal Carcinomatosis Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint)

FAQs

• What was the peritoneal carcinomatosis total market size, the market size by therapies, market share (%) distribution in 2020, and what would it look like in 2040? What are the contributing factors for this growth?
• At what CAGR, peritoneal carcinomatosis market is expected to grow at the 7MM level during the study period (2020–2040)?
• How is Japan's peritoneal carcinomatosis competitive landscape evolving? 
• What are the disease risks, burdens, and unmet needs of peritoneal carcinomatosis? 
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to peritoneal carcinomatosis?
• What is the historical and forecasted peritoneal carcinomatosis patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• What factors are affecting the increase in the diagnosis of symptomatic cases?
• What are the current options for the treatment of peritoneal carcinomatosis? What are the current treatment guidelines for the treatment of peritoneal carcinomatosis in the US and Europe?
• How many companies are developing therapies for the treatment of peritoneal carcinomatosis?
• Which key designations have been granted for the emerging therapies for peritoneal carcinomatosis?
• What is the cost burden of approved therapies on the patient?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies? Focus on reimbursement policies.